Literature DB >> 18786729

The InterSePT suicide scale for prediction of imminent suicidal behaviors.

David W Ayer1, Karu Jayathilake, Herbert Y Meltzer.   

Abstract

The present study examined the ability of the International Suicide Prevention Trial (InterSePT) Scale for Suicidal Thinking (ISST) and the Calgary Depression Scale (CDS) to predict suicide attempts or hospitalizations to prevent attempts (referred to as Type 1 events) during the InterSePT trial [Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A., Bourgeois, M., Chouinard, G., Islam, M.Z., Kane, J., Krishman, R., Lindenmayer, J.P., Potkin, S., 2003. Clozapine treatment for suicidality in schizophrenia. Archive of General Psychiatry 60, 82-91]. The primary goal of this analysis was to determine if the ISST and CDS ratings indicated that the raters, an unblinded (UP) and a blinded psychiatrist (BP) using the ISST, and a blinded rater using the CDS, were able to identify those patients who had a Type 1 event. The ratings of patients adjudged to have experienced a Type 1 event (Group 1) were compared with patients who did not (Group 2). The ISST and the CDS ratings obtained 2-8 weeks prior to a Type 1 event (Pre-1) and Pre-2, the rating immediately prior to Pre-1, obtained 2-12 weeks before Pre-1, were analyzed to test the hypothesis that the difference between Pre-2 and Pre-1 ratings for the Group 1 patients was significantly greater than the difference in the comparable ratings for Group 2 patients. The prediction that patients with Type 1 events would show greater worsening in ISST and CDS ratings between Pre-2 and Pre-1 than the Group 2 patients was confirmed. However, the sensitivity and specificity of a worsening in ratings was not sufficient to provide definitive warning of an impending Type 1 event. Other characteristics of the patients with Type 1 events provide additional warning: e.g. overall higher ratings on these scales, slower improvement in suicidality during treatment, and previous number of suicide attempts. These results indicate that the ISST and CDS may provide some additional information that can assist clinical decision making regarding suicidal risk in patients with schizophrenia or schizoaffective disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786729     DOI: 10.1016/j.psychres.2007.07.029

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

1.  SIBAT-A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.

Authors:  Larry Alphs; Dong-Jing Fu; David Williamson; Carol Jamieson; John Greist; Magdalena Harrington; Jean-Pierre Lindenmayer; Cheryl McCullumsmith; David V Sheehan; Richard C Shelton; Paul Wicks; Carla M Canuso
Journal:  Innov Clin Neurosci       Date:  2022 Apr-Jun

2.  Attitudes of acceptability and lack of condemnation toward suicide may be predictive of post-discharge suicide attempts.

Authors:  Igor Galynker; Zimri S Yaseen; Jessica Briggs; Fumitaka Hayashi
Journal:  BMC Psychiatry       Date:  2015-04-16       Impact factor: 3.630

3.  The relationship between depressive syndrome and suicidal risk in patients with acute schizophrenia.

Authors:  Dario Bagaric; Petrana Brecic; Drazenka Ostojic; Vlado Jukic; Ana Goles
Journal:  Croat Med J       Date:  2013-10-28       Impact factor: 1.351

4.  Reliability, validity and factorial structure of the Arabic version of the international suicide prevention trial (InterSePT) scale for suicidal thinking in schizophrenia patients in Doha, Qatar.

Authors:  Samer Hammoudeh; Suhaila Ghuloum; Ziyad Mahfoud; Mark Opler; Anzalee Khan; Arij Yehya; Abdulmoneim Abdulhakam; Azza Al-Mujalli; Yahya Hani; Reem Elsherbiny; Hassen Al-Amin
Journal:  BMC Psychiatry       Date:  2016-12-07       Impact factor: 3.630

5.  A Smartphone-Based Intervention as an Adjunct to Standard-of-Care Treatment for Schizophrenia: Randomized Controlled Trial.

Authors:  S Nassir Ghaemi; Oleksandr Sverdlov; Joris van Dam; Timothy Campellone; Robert Gerwien
Journal:  JMIR Form Res       Date:  2022-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.